Ideas & Impact › Resources › Accelerating Access to Optimal Child-Friendly Antiretroviral Formulations

While clinical trials have demonstrated the benefits of Dolutegravir (DTG) and Lopinavir-Ritonavir (LPV/r) over Nevirapine (NVP)-based regimens, many children are still on NVP-based regimens. Even when LPV/r syrup is available, it is poorly tolerated by children and difficult to store due to its cold chain requirement. This brief provides an overview of EGPAF’s continued work under Unitaid’s POC EID grant to accelerate sustainable access to optimal pediatric ARV formulations in five implementing countries, Côte d’Ivoire, Eswatini, Lesotho, Mozambique and Zimbabwe.

Explore Related Resources

Search More Resources

Resource

Research Review: Pediatric and Maternal HIV at AIDS 2026

Published September 2026

After reviewing the research on pediatric HIV presented at AIDS 2026, here is how we are putting these findings into practice.

Topics:

Adolescents,

Children,

Maternal and Child Health,

Mothers and Infants,

Pediatric HIV,

Research

Countries:

Global

Issue Briefs

Common Ground for Global Health Policy Brief: Adolescent HIV

Published August 2026

This policy brief explains the current landscape of adolescent HIV, with a particular focus on adolescent girls and the barriers they face regarding prevention, diagnosis, and treatment. It also provides recommendations for U.S. policymakers.

Topics:

Adolescents,

Advocacy,

HIV,

Pediatric HIV

Countries:

Global

Poster

From Mortality Review to Mortality Reduction: The Importance of Embedding Routine Pediatric HIV Death Audits in Tanzania

Published August 2026

We assessed the implementation of standardized pediatric mortality audits and associated programmatic responses on mortality trends among CLHIV in Tanzania.

Topics:

Pediatric HIV,

Research

Countries:

Tanzania